Skip to main content

Table 2 Molecular characteristics of the tumors

From: Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy

  

Pt. number

%

ER

(-)

68

45.0

 

(+)

83

55.0

PR

(-)

92

60.9

 

(+)

59

39.1

bcl-2

(-)

59

39.1

 

(+)

92

60.9

p53

0

47

31.1

 

1–25%

58

38.4

 

26–50%

11

7.3

 

51–75%

8

5.3

 

76–100%

27

17.9

c-erbB2

0

65

43.0

 

+

36

23.8

 

++

20

13.2

 

+++

30

19.9

Ki-67

< 5%

67

44.4

 

≥5%

84

55.6